Neurotechnology

Brain-Computer Interfaces

Emerging4/5 relationships sourcedProfile verified Jul 22, 2026

30-Second Executive Brief

Executive Assessment

Brain-Computer Interfaces functions as an emerging technology within Neurotechnology, backed by 70% sourcing coverage, with accelerating strategic relevance.

  • Maintains 5 mapped relationships across the graph
  • 70% sourcing coverage across sourced relationships
  • Tracked as emerging technology within the Neurotechnology category

Executive Snapshot

Strategic Role
Emerging Technology
Sourcing Coverage
70%
View Methodology →

Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.

Ecosystem Influence
Emerging
Strategic Momentum
Accelerating

Coverage

Mapped Relationships
5
Technology Domains
4

Strategic Implications

  • Central node connecting multiple strategic ecosystems
  • Directly influences technology and capital flows
  • Material relevance to downstream dependency mapping

Top Opportunities

First FDA premarket approval (PMA) of an implantable BCI expected as early as 2026-2027Market estimated to reach $8-12 billion as multiple companies pursue approval in parallel

Top Risks

Long, uncertain FDA approval pathways for implantable devicesSurgical risk and small patient populations slow trial enrollmentNascent commercial reimbursement pathway
Continue to Dependency Graph ↓

An emerging medical-device category using implanted or minimally invasive electrode arrays to translate neural signals into digital commands, initially targeting paralysis and speech-loss patients. Human trials accelerated sharply in 2026, with Neuralink reaching its 26th trial participant, Synchron raising $200 million for a 2026 FDA pivotal trial, and Precision Neuroscience clearing FDA 510(k) review for its Layer 7 Cortical Interface, as industry estimates put the near-term BCI market at $8-12 billion.

Sources

Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.

Evidence

1 source

Relationship Map

The relationships surrounding Brain-Computer Interfaces — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.

Connection type

Sign in free to click a node and explore →

Click any node to make it the new center. Scroll to zoom, drag to pan.

The Story So Far (last 6 months)

Jun 2026: BCI human trials accelerate industry-wideJun 2026: Brain-computer interface trials are taking off

Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.

Brain-Computer Interfaces's Timeline

A sourced, dated history of Brain-Computer Interfaces's key moments — founding to present.

  1. Jun 2026 · BCI human trials accelerate industry-wide

    Neuralink, Synchron and Precision Neuroscience all advanced human clinical programs in the first half of 2026, with MIT Technology Review describing brain-computer interface trials as 'taking off' amid a widening field of competitors.

    Source